Sector
PharmaceuticalsOpen
₹379.25Prev. Close
₹379.25Turnover(Lac.)
₹226.88Day's High
₹379.25Day's Low
₹357.5552 Week's High
₹442.752 Week's Low
₹263.3Book Value
₹103.45Face Value
₹5Mkt Cap (₹ Cr.)
994.92P/E
32.05EPS
11.23Divi. Yield
0.28Earlier this year, Bajaj Healthcare secured formal CMO agreements with customers in the United Kingdom and the European Union to deliver 15 APIs.
The strategic partnership aims to enhance Bajaj Healthcare's presence in the European pharmaceutical market.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.8 | 13.8 | 13.8 | 13.8 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 264.56 | 353.89 | 314.69 | 244.61 |
Net Worth | 278.36 | 367.69 | 328.49 | 258.41 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 656.98 | 410 | 370.17 | 327.1 |
yoy growth (%) | 60.23 | 10.76 | 13.16 | 41.81 |
Raw materials | -377.89 | -263.23 | -242.02 | -215.28 |
As % of sales | 57.51 | 64.2 | 65.38 | 65.81 |
Employee costs | -34.54 | -28.43 | -24.61 | -21.65 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 118.81 | 32.45 | 24.16 | 22.68 |
Depreciation | -16.12 | -12.12 | -11.41 | -11.08 |
Tax paid | -35.71 | -9.95 | -7.85 | -7.49 |
Working capital | 78.78 | 14.98 | 9.66 | 26.86 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 60.23 | 10.76 | 13.16 | 41.81 |
Op profit growth | 184.93 | 12.24 | 8.66 | 27.97 |
EBIT growth | 226.77 | 20.85 | 6.55 | 39.23 |
Net profit growth | 269.37 | 37.94 | 7.4 | 94.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sanjankumar R Bajaj
Joint Managing Director
Anil C Jain
Whole-time Director
Namrata S Bajaj
Whole-time Director
Dhananjay S Halte
Independent Director
Ram B Banarase
Independent Director
Hemant R Karnik
Company Sec. & Compli. Officer
Aakashkumar Kesari
Independent Director
Loukik D Tipnis
Independent Director
Kejal Shah
Whole-time Director
Pakshal Jain
Whole Time Director
Rupesh H Nikam
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bajaj Healthcare Ltd
Summary
Bajaj Healthcare Ltd. is a bulk drug manufacturer established in 1993, serving various Pharmaceuticals, Nutraceuticals and Food industries globally with a spirit of scrupulousness. The Company commenced its operations in 1993 with a single unit at Tarapur. It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra. It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities. In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility. In 2013, it set up another API and Intermediate manufacturing plant at Panoli, Ankleshwar and acquired and set up an Intermediate Unit in Tarapur MIDC, near Mumbai in November, 2014.In FY 2019-20, the Company acquired Intermediates manufacturing Unit at MIDC, Tarapur Maharashtra and also agreed to acquire Four Manufacturing facilities, comprising of three APIs manufacturing facilities, one Engineering Unit, at MIDC Tarapur, Maharashtra along with an Industrial Plot at Dahej, Gujarat.The Company started commercial operations at Panoli Unit, in Bharuch from May 11, 2022. In 2021-22, it launched a Nutraceutical named Magnesium L-Threonate; commenced commercial production at Tarapur, for Nimesulide API, used for relief from pain and prevention of fe
Read More
The Bajaj Healthcare Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹360.5 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bajaj Healthcare Ltd is ₹994.92 Cr. as of 22 Oct ‘24
The PE and PB ratios of Bajaj Healthcare Ltd is 32.05 and 3.57 as of 22 Oct ‘24
The 52-week high/low is the highest and lowest price at which a Bajaj Healthcare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bajaj Healthcare Ltd is ₹263.3 and ₹442.7 as of 22 Oct ‘24
Bajaj Healthcare Ltd's CAGR for 5 Years at N/I%, 3 Years at -0.23%, 1 Year at -8.51%, 6 Month at 13.49%, 3 Month at 2.50% and 1 Month at -7.41%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice